~~What is claimed is:~~

~~1. An isolated nucleic acid encoding an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166.~~

~~2. An isolated nucleic acid encoding an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164.~~

~~3. The isolated nucleic acid of claim 2, wherein the nucleic acid further comprises a nucleic acid sequence encoding an antibody heavy chain constant region.~~

~~4. The isolated nucleic acid of claim 3, wherein the antibody heavy chain constant region is an IgG1 constant region.~~

~~5. A recombinant expression vector comprising the nucleic acid of any one of claims 1 to 4.~~

~~6. A host cell comprising the recombinant expression vector of claim 5.~~

~~7. The host cell of claim 6, wherein the host cell is selected from the group consisting of E. coli, Pseudomonas, Bacillus, Streptomyces, yeast, a mammalian cell, a plant cell, and an insect cell.~~

~~8. The host cell of claim 7, wherein the mammalian cell is selected from the group consisting of CHO, YB/20, NSO, SP2/0, Rl.1, B-W, L-M, COS 1, COS 7, BSCl, BSC40, and BMTlO cells, and a human cell.~~

~~9. A method of synthesizing an antibody that binds EGFR comprising culturing the host cell of claim 7 in a culture medium.~~

~~10. Use of an immunoconjugate comprising a cytotoxic agent conjugated to an isolated anti-Epidermal Growth Factor Receptor (EGFR) antibody in the manufacture of a medicament for the treatment of a tumor which contains amplified EGFR, wherein the anti-EGFR antibody comprises~~

~~a heavy chain variable region comprising the amino acid sequence set forth in~~

~~SEQ ID NO: 164, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166.~~

~~11. The use of claim 10, wherein the anti-EGFR antibody comprises an IgG1 heavy chain constant region.~~

~~12. The use of claim 11 wherein the anti-EGFR antibody comprises a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 48.~~

~~13. The use of claims 10 or 11, wherein the immunoconjugate is used in combination with temozolomide.~~